Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma PatientsCentre Hospitalier Universitaire VaudoisBone & Cancer Foundation
Phase I trial of patient-oriented vaccina- tion in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci. 2004; 95: 77-84.Noguchi M, Itoh K, Suekane S, et al: Phase I trial of patient- oriented vaccination in HLA-A2 positive patients with metastatic ...
Both HLA-A2 positive and HLA-A2 negative individuals can mount responses against HLA-A2 bound peptidesHumansMedication ErrorsClinical Pharmacy Information SystemsDecision Support Systems, ClinicalMedication Systems, HospitalUnited StatesJ Biomed Inform. 2005 Aug;38(4):259-61....
Analysis of the human cytomegalovirus pp65-directed T-cell response in healthy HLA-A2-positive individuals 来自 国家科技图书文献中心 喜欢 0 阅读量: 24 作者:J Schalich,O Vytvytska,W Zauner,MB Fischer,M Buschle,G Aichinger,CS Klade 摘要: Human cytomegalovirus (HCMV) is contained by T-...
A COMBINATION OF EXOSOMES CARRYING TSA DERIVED FROM HLA-A2-POSITIVE HUMAN WHITE BUFFY COAT AND POLYI:C FOR USE AS A SUBCELLULAR ANTITUMOR VACCINATION To improve its antitumor effect, we used human leukocyte antigen –A2 (HLA-A2)-positive human dendritic cell (DC)-derived DEXs (DC-derived exoso...
Bixby DL, Yannelli JR (1998) CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA- A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer. Int J Cancer 78: 685-694....
HLA-A2-positive and HLA-A2-negative patient characteristics.Annika C. KarlssonAstrid K.N. IversenJoan M. ChapmanTulio de OliveiraGerald SpottsAndrew J. McMichaelMiles P. DavenportFrederick M. HechtDouglas F. Nixon
For HLA-A2 positive person glypican-3 (GPC3) origin cancer refusal antigen peptide and the medicine which includes thisIt is to offer the expedient which makes the immunity medical therapy which deals with 40% of the various cancer patients who GPC3 high are revealed possible by the fact that...
Eligible patients were required to have failed prior standard cancer therapies and to be positive for the HLA-A2, -A24 or -A3 (A3, A11, A31 and A33) supertype. Three sets of 8 candidate peptides (24 peptides in total) were provided for vaccination to HLA-A2+, HLA-A24+ and HLA-A3+...
Ren WN,Chang CK,Fan HH,et al.A combination of exosomescarrying TSA derived from HLA-A2-positive human white buffycoat and polyI:C for use as a subcellular antitumor vaccination. Journal of Immunoassay and Immunochemistry . 2011A COMBINATION OF EXOSOMES CARRYING TSA DERIVED FROM HLA-A2-POSITIVE ...